[PDF] MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody,

mbs303MBS303MSC303 (MBS303 as the intravenous formulation, MSC303 as the subcutaneous formulation) is an innovative CD20CD3 T-cell engager. MBS303 has initiated clinical trialsMBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. The